Related Experiment Video
Updated: May 1, 2026

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
Neuroprotective strategies for cognitive decline in type 2 diabetes
Flavia A Cimini1, Aida Cuenca-Royo2, Maria Gomis-Gonzalez2
1Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
None:
Type 2 diabetes (T2D) is increasingly associated with cognitive impairment and dementia, reflecting the combined impact of metabolic dysregulation, vascular injury, neuroinflammation, and defective brain insulin signaling. While this link is now well recognized, it remains unclear whether cognitive decline in T2D is modifiable. This review focuses on emerging neuroprotective strategies, highlighting both pharmacological and lifestyle-based interventions. Recent evidence indicates that some glucose-lowering agents, notably metformin, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists, may exert pleiotropic effects on brain metabolism, inflammation, and vascular integrity beyond glycemic control. We propose a conceptual shift in T2D management in which cognitive preservation becomes an explicit therapeutic objective, integrating metabolic control with targeted brain-protective approaches.
Related Concept Videos
Type II Diabetes II: Pathophysiology
Diabetes Mellitus: Type 2 and Gestational
Type I Diabetes II: Pathophysiology
Alzheimer's Disease: Treatment
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Alzheimer Disease l: Introduction

